Johnson & Johnson (NYSE:JNJ) Shares Sold by Angeles Investment Advisors LLC

Angeles Investment Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,701 shares of the company’s stock after selling 496 shares during the quarter. Angeles Investment Advisors LLC’s holdings in Johnson & Johnson were worth $824,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $29,000. Crowley Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $503,000. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after purchasing an additional 1,772,706 shares in the last quarter. Community Bank N.A. increased its position in shares of Johnson & Johnson by 5.4% during the fourth quarter. Community Bank N.A. now owns 45,821 shares of the company’s stock worth $6,627,000 after purchasing an additional 2,341 shares in the last quarter. Finally, Napatree Capital LLC increased its position in shares of Johnson & Johnson by 30.4% during the fourth quarter. Napatree Capital LLC now owns 5,956 shares of the company’s stock worth $861,000 after purchasing an additional 1,388 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on JNJ shares. Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Price Performance

JNJ opened at $163.40 on Monday. The stock’s 50-day moving average price is $156.99 and its 200 day moving average price is $156.17. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market cap of $393.76 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.